Health & BiotechnologyEconomy
China's Biotech Surge at ASCO 2026 Challenges US Dominance
Chinese biotech firms set records at ASCO 2026 with 95 abstracts and a $10.5B Pfizer-Innovent deal, fueling concerns over US drug dominance.
—5 min read
Category
1 article
Chinese biotech firms set records at ASCO 2026 with 95 abstracts and a $10.5B Pfizer-Innovent deal, fueling concerns over US drug dominance.